On the 12th, Shanghai Stock Exchange and China Securities Index Co., Ltd. officially announced the relevant arrangements for the release of the Shanghai Science and Innovation Board biomedical index (hereinafter referred to as the science and innovation biological index).
In order to timely reflect the performance of the securities listed on the science and innovation board and provide the market with multi-dimensional investment targets and performance benchmarks, Shanghai Stock Exchange and China Securities Index Co., Ltd. will officially release the Shanghai Science and Innovation Board biomedical index on May 9, 2022. After liquidity screening, the SSE Kechuang board biomedical index selects 50 securities of Listed Companies in the fields of biomedicine, biomedical engineering, bio agriculture, biomass energy and other biological industries with large market value from the Kechuang board market as the index sample to reflect the overall performance of the securities of Listed Companies in the representative biomedical industry in the Kechuang board market.
includes 50 shares
It is understood that after liquidity screening, Kechuang biological index selects 50 securities of Companies in the fields of biomedicine, biomedical engineering and other biological industries with large market value as the index sample. The top five heavyweights are Shanghai Junshi Biosciences Co.Ltd(688180) , Zhejiang Orient Gene Biotech Co.Ltd(688298) , Cansino Biologics Inc(688185) , Shanghai Medicilon Inc(688202) and Qingdao Haier Biomedical Co.Ltd(688139) , with a total weight of 33%.
In the long run, the pharmaceutical industry is a star industry worthy of investment. During the “14th five year plan” period, a new development pattern with China’s big cycle as the main body and international and Chinese double cycles promoting each other was accelerated, and China’s biomedical market entered a high-quality development stage. The new development stage also puts forward higher requirements for the biomedical industry. There is an urgent need to accelerate innovation driven transformation and provide strong support for building a new development pattern.
Biomedicine is a national strategic emerging industry and one of the core areas supported by the science and innovation board. It has formed a certain scale and characteristics, attracting many representative biomedical enterprises to land on the science and innovation board. Biomedicine is also one of the industry themes with the most prominent overall profitability in the science and innovation board.
The latest financial report shows that in 2021, the performance of enterprises in the biomedical industry of the science and Innovation Board maintained a rapid growth rate, with a year-on-year increase of 54% (excluding losses). The median gross profit margin and net profit margin were 73% and 24% respectively, ranking first in all industries.
The organization is also optimistic about the development of the pharmaceutical industry. Sun Yuanyuan, deputy general manager of China Industrial Securities Co.Ltd(601377) director and co chief of medicine, said that the total amount and quality of the biomedical industry continued to grow. On the one hand, the average annual growth rate of operating revenue and total profit of the pharmaceutical industry in the 14th five year plan remains above 8%, and the proportion of added value in all industries has increased to about 5%. The pharmaceutical industry between sectors still has a certain comparative advantage; The R & D investment of the whole industry will increase by more than 10% annually, and will still increase in excess in the next five or even ten years.
On the other hand, under the policy guidance and technological accumulation, the China Meheco Group Co.Ltd(600056) industry is experiencing innovation from quantity to quality, new products are launched one after another, and the pace of domestic substitution is accelerating day by day. At the same time, consumption upgrading continues to bring new demand release, rigid demand resonates with optional demand, and promotes the continuous improvement and optimization of industrial structure. Under the opportunity of innovation and upgrading on the supply side and continuous capacity expansion on the demand side, “hard technology + new consumption” makes the pharmaceutical sector show its true growth.
“At present, the biomedical listed enterprises on the science and innovation board have the attributes of undervalued value, high growth and high R & D, and the investment value is prominent. At present, the overall P / E ratio is less than 30 times (excluding losses), which is at a very low level since the opening of the science and innovation board.” Huitianfu fund stakeholders said in an interview with the securities times that the index, as an increasingly important observation dimension and investment tool of the capital market, guides the capital flow and plays an important role in promoting the concept of long-term investment, value investment and rational investment.
enrich the scientific innovation index system
Kechuang biological index is another major industry theme index representing the Kechuang board market after Kechuang 50 index and Hunan Creator Information Technologies Co.Ltd(300730) index, which will further enrich the Kechuang board market index system.
In the sample of scientific innovation biological index, the company’s overall “hard technology” attribute is outstanding, and innovative drug enterprises cover many treatment fields, such as cancer, tumor, immune system disease, infectious disease, etc; In vitro diagnosis and vaccine enterprises are actively fighting in the front line of anti epidemic, giving full play to their professional advantages and helping with epidemic prevention and control; Both Zhejiang Orient Gene Biotech Co.Ltd(688298) and other leading enterprises with annual revenue of more than 10 billion, and Cansino Biologics Inc(688185) and other innovative drug enterprises listed according to the fifth set of standards of the science and innovation board, showing the enabling effect of the inclusive soil of the science and innovation board system.
With the steady progress of the construction of the science and innovation board and the continuous expansion of the number of securities, investors’ diversified observation and investment demand have increased significantly. It is necessary to enrich the index system of the science and innovation board to comply with the voice of the market. The industry theme is a relatively mature and widely used index type. The preparation scheme is relatively transparent, clear and easy to understand. It is also one of the main development directions in the index field in recent years.
The sampling, weighting, adjustment mechanism and other rules of Kechuang biological index are in line with the mainstream international practices, basically consistent with the published Kechuang 50 and Hunan Creator Information Technologies Co.Ltd(300730) indexes, and are widely accepted by investors.
As a subdivision ruler reflecting the trend of important themes of the science and innovation board, the launch of the science and innovation biological index will have three “beneficial” positive effects:
First, it is conducive to further increase the observation dimension of the science and innovation board. Index release can enrich the observation dimension of various investors and the analysis dimension of financial media;
Second, it is conducive to serving the majority of investors. In the future, the issuance of index products will provide investors with richer tools to participate in the development of science and innovation board and share economic growth, so as to better meet the needs of asset allocation and wealth management;
Third, it is conducive to optimizing the allocation of resources. The science and innovation theme index focuses on leading companies in strategic emerging industries, which is conducive to guiding resources to further tilt towards hard technology companies represented by the science and innovation board.
